Pembrolizumab for fallopian tube neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Nov 2018: Trial registered, NCT03732950
  2. 6 Mar 2019: Trial started, NCT03732950

The trials

NCT03732950: Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

State
Under way
Phase
Phase 2
People
5 taking part
Started
6 Mar 2019
Primary completion
5 Dec 2023
Arms
Treatment (pembrolizumab)
Results
None posted
  1. 7 Nov 2018: Trial registered
  2. 6 Mar 2019: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as Keytruda, Keytruda qlex component pembrolizumab, Pembrolizumab 200 mg, Pembrolizumab Injection [Keytruda], Pembrolizumab SC.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.